In: Cerebral Cortex, 2017, vol. 27, no. 6, p. 3217-3230
|
In: Osteoporosis International, 2015, vol. 26, no. 12, p. 2763-2771
|
In: Brain Structure and Function, 2015, vol. 220, no. 3, p. 1789-1790
|
In: Social Politics: International Studies in Gender, State & Society, 2018, vol. 25, no. 1, p. 118-147
|
In: The American Journal of Clinical Nutrition, 2016, vol. 104, no. 5, p. 1318-1326
|
In: Virus Evolution, 2018, vol. 4, no. 2, p. -
|
In: Clinical Chemistry and Laboratory Medicine (CCLM), 2017, vol. 55, no. 4, p. 571-577
|
In: Blood, 2020, vol. 137, no. 10, p. 1365–1376
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B cell receptor immunoglobulins (BcR IG). Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR IG stereotypy in CLL has important implications for understanding disease...
|
In: Blood, 2020, vol. 135, no. 21, p. 1859–1869
Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients...
|
In: Blood, 2020, vol. 135, no. 15, p. 1244–1254
CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The cutoff value for the extensively validated 30% of positive CLL cells is able to separate CLL patients into 2 subgroups with different prognoses, but it does not consider the pattern of CD49d expression. In the present study, we analyzed a cohort of 1630 CLL samples and identified the presence of ∼20% of CLL...
|